Viestar secures new funding round exceeding RMB 100M for global leadership in precision endoscopy

Recently, Viestar announced the completion of a new funding round exceeding RMB 100 million. This round was jointly invested by Efung Zhuohua Fund, Huabin Fengtai Private Fund, and YOFC Fund. The proceeds will be primarily used to support the ongoing R&D, scaled production, clinical application promotion, and global commercialization of the company's confocal microendoscopy products.

As a high-end medical device enterprise focused on early tumor precision diagnosis and treatment, Viestar has achieved deep integration of "industry-university-research-medicine-testing" ecosystems. Supported by more than ten Chinese National Key R&D Programs, the company has obtained multiple confocal microendoscopy device registration certificates and earned the National Science and Technology Achievement Certification from the Ministry of Industry and Information Technology, reflecting its internationally advanced technical capabilities.

Viestar has mastered the entire critical technology chain—from key materials and core components to full system integration—for domestically produced confocal microendoscopes. This achievement eliminates dependence on imported equipment and technology, realizing China's goal of creating confocal microendoscopy systems that are "self-sufficient, replicable, and scalable." Furthermore, the company has overcome key manufacturing barriers to build a complete, independent industrial chain for confocal microendoscopy and established a world-leading, large-scale manufacturing base, including the world's largest mass production center for these systems. Viestar is committed to advancing the localization and internationalization of confocal microendoscopy while promoting the global adoption of Chinese technical standards.